Navigation Links
IRS Awards $244,479 Grant to STB Lifesaving Technologies®
Date:11/3/2010

ROCKVILLE, Md., Nov. 3, 2010 /PRNewswire/ -- STB Lifesaving Technologies® today announced that it has been awarded a Qualifying Therapeutic Discovery Project (QTDP) grant from the U.S. government in the amount of $244,479.  

The Qualifying Therapeutic Discovery Project was included in the Health Care Reform Bill to foster medical, life science, and biological innovation in the U.S., and the grant was based upon research expenditures for its lead product, the Fibrin Adhesive STat®, or FAST® dressing.

STB® has conducted successful animal studies for the FAST® dressing with both military and commercial partners and is further supported by published data from the American Red Cross.  

In these published comparative animal studies, Fibrin Adhesive STat®, or FAST® dressing has proven to be functionally superior to commercially available products in significantly reducing blood loss.  The FAST® dressing contains large quantities of the human blood clotting proteins fibrinogen, thrombin, and Factor XIII in a dry form. Once in contact with the wound, the components in the FAST® dressing are instantly activated to form a fibrin clot similar to that which results from the body's own clotting process.

Last month STB® announced that it had completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA).

"This additional funding will accelerate the remaining pre-IND development work and animal studies for the FAST® dressing already underway," said Richard Moscarello, CEO of STB®. "We appreciate the government's continued support for this product which soon will be translated into saving military and civilian lives."

About STB®  

Founded in 2005, STB Lifesaving Technologies® (STB®) is a privately held, pre-clinical stage, biotechnology development company located in Rockville, Maryland. STB® which stands for "stop the bleeding", is focused on developing a comprehensive suite of products to stop serious and life threatening bleeding in trauma and surgical settings. With a strong proprietary position using its all-natural protein technology with five patents and one provisional patent pending, STB®'s products will be indispensable to both the military and civilian medical markets.

www.stblifesaving.com


'/>"/>
SOURCE STB Lifesaving Technologies
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
2. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
3. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
4. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
5. Small Business Innovation Research Program Awards Grant to Biomoda
6. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
7. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
8. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
9. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
10. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
11. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... S.C. , July 10, 2017  BDI ... purchasing and patient support services organization serving specialty ... today the launch of four significant, value-added member ... market insights, better manage reimbursement and improve access ... and factor therapies. ...
(Date:7/5/2017)... 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... received approval from the Israel Securities Authority to dual-list its ... common stock will commence trading on the TASE on July ... market capitalization of the Company, it is expected that Oramed ...
(Date:6/30/2017)... -- AVACEN Medical (AVACEN) announced the publication of new research in the ... its AVACEN Treatment Method to significantly reduce the widespread ... ... ... approximately 200 to 400 million people worldwide according to The National ...
Breaking Medicine Technology:
(Date:7/24/2017)... SANTA CLARA, CA (PRWEB) , ... July 24, 2017 , ... ... government and financial organizations, today announced it has partnered with WALLIX to ... NIST Special Publication 800-171 . , There are a number of ways to address ...
(Date:7/24/2017)... ... July 24, 2017 , ... Anyone who uses scales know they ... would a pharmacist using that same scale to dispense medication. The first example is ... These illustrations show why it is important to have the right balance for the ...
(Date:7/24/2017)... ... 24, 2017 , ... A Southern California-based author has released a new book ... she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle V. Madsen, highlights ... risen above. , In “Memories,” readers get a firsthand look at what Michelle has ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... how to change manufacturers future. , The agency is hammering out a game ... one of the farthest-ranging laws ever to affect FDA-regulated firms. The new law:, ...
(Date:7/24/2017)... ... 24, 2017 , ... “A Short Walk to the Mailbox”: a remarkable memoir ... of published author, Ed Clark. Ed Clark is a church music director and ... a minister of music and worship leader for over fifty years. He has ...
Breaking Medicine News(10 mins):